SVRA Savara Inc Insider Trading

CFO David Lowrance sells 394,528 shares of SVRA at $5.68 for $2.2M; retains 536,032 shares plus 233,750 in options.

David L Lowrance, Chief Financial Officer of Savara Inc, sold 394,528 shares at $5.68 on 2026-06-22 for $2,241,431.93, reducing his non-derivative holdings from 930,560 to 536,032 shares. The company is unprofitable with net income of $-37,284,000.00 (latest full fiscal year) and zero revenue in the most recent quarter, yet carries a market cap of $1,166,035,836.28. Lowrance maintains significant derivative holdings of 233,750 shares via options across six separate awards, indicating his overall stake remains material. The sale occurred while the stock trades at $5.69, near the 52-week high of $7.00 but up 13.4% over the prior 30 days and 12.9% over 90 days—a period of positive momentum. This partial reduction of non-derivative holdings by a CFO of a loss-making biotech warrants monitoring for any accompanying disclosures about funding, operations, or capital strategy shifts.

Director Hawkins bought 48,225 shares of SVRA at $2.04; holdings up 71.7% to 115,466 shares. Company unprofitable with $-26.6M net income.

Director Richard J Hawkins purchased 48,225 shares at $2.04 on 2025-06-20, increasing his holdings by 71.7% from 67,241 to 115,466 shares at a total cost of $98,571.90. His cross-ticker track record shows 3 prior open-market buys with an average 90-day return of +2415.9% and a 100.00% win rate across all holdings, establishing a strong pattern of successful buy-side timing. However, this transaction occurs against a deteriorating backdrop: Savara Inc reported zero revenue in the latest quarter and a full-year net income of $-26,639,000.00 on a $373,327,751.52 market cap, indicating persistent unprofitability. The current price of $2.16 is 57.4% below the 52-week high and down 23.9% over the past 30 days, placing the trade well below recent valuations. While the director's prior success across other equities demonstrates analytical acumen, the concentrated purchase during ongoing fundamental weakness at Savara warrants examination of whether this represents conviction in a turnaround or a timing signal that contradicts broader market deterioration.

Director McCracken bought 10,000 shares of SVRA at $2.08 on 2025-05-29; holds 260.8K shares post-transaction in unprofitable biotech.

McCracken Joseph S, a Director, purchased 10,000 shares at $2.08 on 2025-05-29, increasing his holdings by 4.0% to 260.8K shares. The stock has declined 29.4% in the 30 days since the transaction and is now trading at $2.40, down 52.7% from its 52-week high of $5.07. Savara Inc is a revenue-generating company (latest quarter revenue $0.00) with a net loss of $26.6M and negative full-year earnings, indicating material operational headwinds. McCracken's cross-ticker buy track record shows 1 prior purchase with a 90-day return of -4.5%, and this same-ticker pattern repeats: his prior SVRA buy on 2024-11-19 also yielded -4.5% over 90 days, with a 0% win rate on timing such buys.

Director David A Ramsay bought 150,000 SVRA shares at $2.78 on 2025-03-31, bringing holdings to 2,513,642 shares (+6.3%)

Director David A Ramsay purchased 150,000 shares of Savara Inc for $416,250.00 on 2025-03-31 at $2.78 per share, increasing his stake by 6.3% to 2.51M shares. The buy occurred when the stock traded near the bottom of its 52-week range, 46.4% below the 52-week high, and the 30-day price momentum has improved +14.9% since the purchase. However, this transaction must be contextualized against Ramsay's prior trading record: his one previous purchase at SVRA in November 2024 at the same price point generated a 90-day return of -2.0%, and across all tickers he has a 0% win rate at the 90-day measurement horizon. The company remains deeply unprofitable with net income of $-24,248,000.00 and zero revenue in the latest quarter, making the fundamental backdrop highly uncertain.

Director Joseph McCracken bought 20,000 SVRA shares at $2.95 on 2024-11-19; now holds 210,837 shares.

McCracken purchased 20,000 shares at $2.95, expanding his position by 10.5% to 210,837 shares total. The transaction occurred at a price point near the 52-week low of $2.94, with the stock currently trading at $3.13 and substantially depressed from its $5.59 high. Savara is a loss-making company with $-24.2M net income in its most recent full fiscal year and zero revenue in the latest quarter, indicating a development-stage or pre-revenue business model. The buy at near-52-week-low pricing by a director with meaningful historical stake represents notable insider accumulation in a fundamentally challenged entity, warranting scrutiny of the strategic rationale and broader board conviction about the company's prospects.

Director David Ramsay purchases 100,000 shares of SVRA at $2.88; stock down 47% from 52-week high, company unprofitable with $-24.2M net income.

Director David A. Ramsay purchased 100,000 shares at $2.88 on 2024-11-18, increasing his holdings to 2,323,642 shares. The transaction occurs against a sharply deteriorating stock backdrop: the security has declined 47.0% from its 52-week high of $5.59 and 21.3% over the past 30 days. Savara remains unprofitable with a net loss of $24,248,000 on zero revenue in the latest quarter, indicating the company is in an early-stage or turnaround phase. The director's open-market purchase at depressed valuations, combined with the magnitude of the position increase (+4.5%), warrants examination of whether this reflects insider confidence in recovery prospects or other strategic considerations not evident from price action alone.